Impaired Humoral Response to Second Dose of BNT162b2 Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients in Japan: Prospective Observational Study
1Sapporo City General Hospital, Sapporo, Japan, 2Sapporo Hokuyu Hospital, Sapporo, Japan
Meeting: 2022 American Transplant Congress
Abstract number: 986
Keywords: Antibodies, COVID-19, Kidney transplantation, Vaccination
Topic: Clinical Science » Infection Disease » 25 - Kidney Infectious Non-Polyoma & Non-Viral Hepatitis
Session Information
Session Name: Kidney Infectious Non-Polyoma & Non-Viral Hepatitis
Session Type: Poster Abstract
Date: Sunday, June 5, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
Session Information
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Hall C
*Purpose: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on solid organ transplant (SOT) recipients, with mortality rate up to 22%. The effect of SARS-CoV-2 vaccination are known to have poor responses even after 2nddose in SOT in Europe and the United States. We investigated immune response by detecting SARS-CoV-2 antibody (Ab) post two-doses of messenger RNA (mRNA)-based SARS-CoV-2 vaccinesin Japanese renal transplant recipients as prospective observational study.
*Methods: 352 recipients who have no history of COVID-19, were confirmed no SARS-CoV-2 antibody before vaccination and received 2nd dose of BNT162b2 mRNA vaccine are enrolled in this study.Antibody detection test was performed by using the Roche Elecsys® Anti-SARS-CoV-2 immunoassay after more than 4weeks following 2nddose of it. Negative for N-Ab (0.4U/ml>) and positive for S-Ab (0.8U/ml<) considered to be positive for SARS-CoV-2 Ab.As a healthy control, SARS-CoV-2 Ab was determined in 990 healthy volunteers (HV) as well as 98 kidney donors as control for chronic kidney disease (Donor).
*Results: The rate of positive for S-Ab was 56.2% in recipients while that was 100% in HV and Donor. Titer of S-Ab (U/ml) was 77 in recipients although that was 2400 in HV and 1100 in Donor, respectively, which indicating significantly lower in recipients. (Fig. 1) Interestingly, positive rate for s-Ab by detecting time following 2ndvaccination in recipients was 44% in 4-6 weeks, 54% in 6-8 weeks, 67% in 8-10 weeks, 72% in 10-12 weeks, 80% in 12-weeks, which suggesting that recipients have delayed response to 2ndvaccination while that was 100% in any time point in HV and Donor. (Fig.2) Moreover, to elucidate difference between responder (n=198) and non-responder (n=154) in recipients, we compared clinical background that influencedoutcome. In non-responder, there were significant difference in older age at vaccination, less lymphocyte, previousdoses of rituximab, concomitant use of mycophenolate mofetil and oral administration of more than three immunosuppressants. (Table.1)
*Conclusions: Kidney recipients have delayed response with lower titer of SARS-CoV-2 antibodyfollowing second dose of mRNA-based COVID-19 Vaccine.
To cite this abstract in AMA style:
Sasaki H, Hasegawa K, Miura M, Harada H, Takamoto D, Takada Y, Harada S, Tanaka H. Impaired Humoral Response to Second Dose of BNT162b2 Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients in Japan: Prospective Observational Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/impaired-humoral-response-to-second-dose-of-bnt162b2-messenger-rna-covid-19-vaccine-in-kidney-transplant-recipients-in-japan-prospective-observational-study/. Accessed December 3, 2024.« Back to 2022 American Transplant Congress